Mankind Pharma Limited
Commenced its operations in 1995, Mankind is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic segments as well as several consumer healthcare products. It i...
Key Metrics
EPS
47.75
Current ratio
3.10
Debt/Equity
0.24
Debt/EBITDA
0.81
Interest coverage ratio
69.46
Operating Cashflow to total debt
2.26
Financials
Pros & Cons
Exclusive on TAP Bonds
Here's what we like about this company and potential risks we have identified.
Pros
Established position in the domestic formulations market
Strong operational efficiency and distribution network
Comfortable financial risk profile
Liquidity: Strong
Cons
Limited geographical diversification with high dependence on the domestic market
Susceptibility to regulatory changes and fluctuations in raw material prices
Disclaimer: Tap Bonds gathers data directly from the respective OBPP websites but does not guarantee its accuracy. We do not offer investment advice or endorse the purchase of any securities mentioned, nor do we warrant the reliability of the information collected.
About Mankind Pharma Limited bond.
This comprehensive profile covers key factual information about Mankind Pharma Limited. Commenced its operations in 1995, Mankind is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic segments as well as several consumer healthcare products. It is India’s fourth-largest pharmaceutical company in terms of domestic sales and third-largest in terms of domestic sales volumes. The company has 30 manufacturing across 6 locations, and all of the facilities have necessary accreditations. Ramesh Juneja, Rajeev Juneja and Sheetal Arora are the promoters, and along with their family members they hold 74.88% stake in Mankind and balance shareholding is held with the public and other shareholders. EPS in Mar-2024 was 47.75. Current ratio in Mar-2024 was 3.10. Debt/Equity in Mar-2024 was 0.24. Debt/EBITDA in Mar-2024 was 0.81. Interest coverage ratio in Mar-2024 was 69.46. Operating Cashflow to total debt in Mar-2024 was 2.26. Total revenue for Mar-2025(E) was ₹11514.59. Net income for Mar-2025(E) stood at ₹1919.46. Total assets as of Mar-2024 were ₹11,882.86. Operating cash flow for Mar-2024 was ₹2,152.45. The company’s borrowing relationships include Citi Bank (₹N/A Cr), HDFC Bank Limited (₹N/A Cr), ICICI Bank Limited (₹N/A Cr). Peers and comparison entities consist of Mankind Pharma Limited, Sun Pharmaceutical Industries Limited, Cipla Limited, Torrent Pharmaceuticals Limited. As of Dec 2024, promoters hold N/A% while others hold N/A% of equity. Key strengths include: Established position in the domestic formulations market; Strong operational efficiency and distribution network; Comfortable financial risk profile; Liquidity: Strong. Key risks include: Limited geographical diversification with high dependence on the domestic market; Susceptibility to regulatory changes and fluctuations in raw material prices. Leadership team details include Anil Kumar (Chief Scientific Officer), Arjun Juneja (Chief Operating Officer), Ashutosh Dhawan (Chief Financial Officer), Atish Majumdar (Senior President), Bharat Anand (Independent Director), Pradeep Chugh (Company Secretary & Compliance Officer), Prakash Agarwal (President), Rajeev Juneja (Vice Chairman & Mng.Director), Ramesh Juneja (Chairman & Wholetime Director), Sanjay Koul (Chief Marketing Officer), Satish Kumar Sharma (Whole Time Director), Sheetal Arora (WholeTime Director & CEO), Surendra Lunia (Independent Director), Tilokchand Punamchand Ostwal (Independent Director), Vijaya Sampath (Independent Director), Vivek Kalra (Independent Director). This detailed corporate overview is structured to provide a thorough understanding of all available data points, enhance search visibility, and support investor analysis.